OptraHealth sues Invitae over genetic testing chatbot

OptraHealth has filed a patent infringement lawsuit against Invitae that centres on the latter’s Gia chatbot that offers genetic testing and advice.

According to the complaint filed at the US District Court of California on May 20, Invitae has infringed US patent 10,754,882, which OptraHealth received in August 2020.

The patent-in-suit covers a conversational digital genetic assistant that provides genetic education and patient engagement.

According to OptraHealth, it invented specific methods in which health reports are retrieved through a machine-assisted interrogation process consisting of a personal assistance device, a reporting system, and knowledge-graphing system, and a query-interrogation system.

The complaint noted that at the time of the invention, retrieving and providing accurate results of health reports was time-consuming and inefficient.

“OptraHealth’s innovations address these and other issues, providing concrete technological improvements, including applying machine-learning to the task to automate the process, using a personal assistance device to provide an interface for a query-interrogation system, and applying a knowledge-graphing system to provide the accurate results to the user,” stated the complaint.

According to its website, Invitae’s genetic information assistant is a HIPAA-compliant diagnostic chatbot.

The filing alleged that this Gia Chatbot includes an infringing “genetic information assistant” or personal assistance device that enables a customer to chat with the Gia Chatbot and review the results of genetic testing results.

The complaint states that Invitae has been notified of direct and indirect infringement of the ‘882 patent since 2021, and the defendant continues to “aid up and abet” infringement by others.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.